Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Recent FDA-approved agents are being used in a variety of combinations and settings, explains Frankfurt. For example, a BCL-2 inhibitor is currently being studied in combination with hypomethylating agents, decitabine and azacitidine, as well as low-dose cytarabine to treat patients with AML.

PD-1 inhibitors are also being used in combinations to treat leukemia and myelodysplastic syndrome.

Olga Frankfurt, MD

Articles

Dr. Frankfurt on the Future of AML Treatments